RFL - Rafael gains Orphan Drug designation for devimistat for biliary duct cancer

Sarah Silbiger/Getty Images News The FDA has granted Orphan Drug designation to devimistat, a candidate from Rafael Pharmaceuticals for liver and intrahepatic bile duct cancer The conditions are also known as biliary tract cancer, and  cholangiocarcinomas of the bile duct and gall bladder. Devimistat is currently in phase 3 for pancreatic cancer and relapsed or refractory acute myeloid leukemia. Earlier this week, Rafael Holdings announced it would merge with Rafael Pharmaceuticals to create a late-stage, clinical oncology company. Rafael shares closed today up 4.7% to $50.72.

For further details see:

Rafael gains Orphan Drug designation for devimistat for biliary duct cancer